PULMONX CORP (LUNG)
US7458481014 - Common Stock
Overall LUNG gets a fundamental rating of 3 out of 10. We evaluated LUNG against 195 industry peers in the Health Care Equipment & Supplies industry. The financial health of LUNG is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LUNG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
LUNG had negative earnings in the past year.
LUNG had a negative operating cash flow in the past year.
LUNG had negative earnings in each of the past 5 years.
In the past 5 years LUNG always reported negative operating cash flow.
1.2 Ratios
LUNG's Return On Assets of -34.23% is in line compared to the rest of the industry. LUNG outperforms 42.05% of its industry peers.
With a Return On Equity value of -51.43%, LUNG perfoms like the industry average, outperforming 47.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.23% | ||
| ROE | -51.43% | ||
| ROIC | N/A |
ROA(3y)-28.44%
ROA(5y)-27.25%
ROE(3y)-38.29%
ROE(5y)-48.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUNG's Gross Margin of 73.90% is amongst the best of the industry. LUNG outperforms 84.10% of its industry peers.
In the last couple of years the Gross Margin of LUNG has grown nicely.
The Profit Margin and Operating Margin are not available for LUNG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.49%
GM growth 5Y3.76%
2. Health
2.1 Basic Checks
LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUNG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUNG has been increased compared to 5 years ago.
LUNG has a worse debt/assets ratio than last year.
2.2 Solvency
LUNG has an Altman-Z score of -0.28. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
LUNG has a Altman-Z score of -0.28. This is comparable to the rest of the industry: LUNG outperforms 45.13% of its industry peers.
LUNG has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
LUNG has a Debt to Equity ratio (0.30) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.28 |
ROIC/WACCN/A
WACC10.33%
2.3 Liquidity
LUNG has a Current Ratio of 6.50. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG has a Current ratio of 6.50. This is amongst the best in the industry. LUNG outperforms 81.03% of its industry peers.
A Quick Ratio of 5.77 indicates that LUNG has no problem at all paying its short term obligations.
The Quick ratio of LUNG (5.77) is better than 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.5 | ||
| Quick Ratio | 5.77 |
3. Growth
3.1 Past
LUNG shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.63%.
LUNG shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.96%.
LUNG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.98% yearly.
EPS 1Y (TTM)-0.63%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q5.26%
Revenue 1Y (TTM)27.96%
Revenue growth 3Y28.02%
Revenue growth 5Y27.98%
Revenue growth Q2Q24.94%
3.2 Future
LUNG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.84% yearly.
Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 21.35% on average per year.
EPS Next Y-17.85%
EPS Next 2Y0.77%
EPS Next 3Y6.13%
EPS Next 5Y10.84%
Revenue Next Year21.5%
Revenue Next 2Y20.03%
Revenue Next 3Y20.09%
Revenue Next 5Y21.35%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LUNG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.77%
EPS Next 3Y6.13%
5. Dividend
5.1 Amount
No dividends for LUNG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PULMONX CORP
NASDAQ:LUNG (4/26/2024, 7:02:10 PM)
After market: 7.28 0 (0%)7.28
-0.02 (-0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap282.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.23% | ||
| ROE | -51.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.9% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.5 | ||
| Quick Ratio | 5.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-0.63%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-17.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.96%
Revenue growth 3Y28.02%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y